First patient dosed successfully in YUKON, Ph. 1 study of second-generation DSR product (DSR 2.0) MOJAVE, US Ph. 1/2a randomized controlled multi-center study of DSR 2.0, on track to start in H1 2023 ...
Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces the completion of enrollment in its phase 2a SAHARA proof-of-concept study ...
Ghent, Belgium – 15 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback